These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10091614)

  • 1. CYP2D6 polymorphism and Parkinson's disease susceptibility.
    Sabbagh N; Brice A; Marez D; Dürr A; Legrand M; Lo Guidice JM; Destée A; Agid Y; Broly F
    Mov Disord; 1999 Mar; 14(2):230-6. PubMed ID: 10091614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson's disease].
    Durić G; Svetel M; Nikolaevic SI; Dragadević N; Gavrilović J; Kostić VS
    Vojnosanit Pregl; 2007 Jan; 64(1):25-30. PubMed ID: 17304721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of effect of seven functional mutations in the CYP2D6 gene in Parkinson's disease.
    Joost O; Taylor CA; Thomas CA; Cupples LA; Saint-Hilaire MH; Feldman RG; Baldwin CT; Myers RH
    Mov Disord; 1999 Jul; 14(4):590-5. PubMed ID: 10435495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 gene polymorphism as a probable risk factor for Alzheimer's disease and Parkinson's disease with dementia.
    Gołab-Janowska M; Honczarenko K; Gawrońska-Szklarz B; Potemkowski A
    Neurol Neurochir Pol; 2007; 41(2):113-21. PubMed ID: 17530572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease.
    Planté-Bordeneuve V; Davis MB; Maraganore DM; Marsden CD; Harding AE
    J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):911-3. PubMed ID: 8057112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.
    Ur Rasheed MS; Mishra AK; Singh MP
    Neurochem Res; 2017 Dec; 42(12):3353-3361. PubMed ID: 28871472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease, CYP2D6 polymorphism, and age.
    Payami H; Lee N; Zareparsi S; Gonzales McNeal M; Camicioli R; Bird TD; Sexton G; Gancher S; Kaye J; Calhoun D; Swanson PD; Nutt J
    Neurology; 2001 May; 56(10):1363-70. PubMed ID: 11376189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease and CYP2D6 polymorphism in Asian populations: A meta-analysis.
    Persad AS; Stedeford T; Tanaka S; Chen L; Banasik M
    Neuroepidemiology; 2003; 22(6):357-61. PubMed ID: 14557687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians.
    Legrand-Andréoletti M; Stücker I; Marez D; Galais P; Cosme J; Sabbagh N; Spire C; Cenée S; Lafitte JJ; Beaune P; Broly F
    Pharmacogenetics; 1998 Feb; 8(1):7-14. PubMed ID: 9511176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 polymorphism in Parkinson's disease: the Rotterdam Study.
    Harhangi BS; Oostra BA; Heutink P; van Duijn CM; Hofman A; Breteler MM
    Mov Disord; 2001 Mar; 16(2):290-3. PubMed ID: 11295783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson's disease.
    Singh M; Khanna VK; Shukla R; Parmar D
    Dis Markers; 2010; 28(2):87-93. PubMed ID: 20364044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease.
    Tsuneoka Y; Matsuo Y; Ichikawa Y; Watanabe Y
    Metabolism; 1998 Jan; 47(1):94-6. PubMed ID: 9440484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between GSTM1-null and CYP2D6-deficient alleles in the pathogenesis of Parkinson's disease.
    Santt O; Baranova H; Albuisson E; Bignon YJ; Lucotte G
    Eur J Neurol; 2004 Apr; 11(4):247-51. PubMed ID: 15061826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
    Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
    Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P450 enzymes and Parkinson's disease: the story so far.
    Riedl AG; Watts PM; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):212-20. PubMed ID: 9539332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 polymorphism is not associated with essential tremor.
    Agúndez JA; Jiménez-Jiménez FJ; Tejeda R; Ledesma MC; Ortí-Pareja M; Gasalla T; Molina JA; Ruiz J; Coria F; Duarte J; Vázquez A; Ladero JM; Benítez J
    Eur Neurol; 1997; 38(2):99-104. PubMed ID: 9286632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of A313 G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson's disease.
    Vilar R; Coelho H; Rodrigues E; Gama MJ; Rivera I; Taioli E; Lechner MC
    Eur J Neurol; 2007 Feb; 14(2):156-61. PubMed ID: 17250723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism.
    Bon MA; Jansen Steur EN; de Vos RA; Vermes I
    Neurosci Lett; 1999 May; 266(2):149-51. PubMed ID: 10353349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6*4 polymorphism is not associated with Parkinson's disease and has no protective role against Alzheimer's disease in the Korean population.
    Woo SI; Kim JW; Seo HG; Park CH; Han SH; Kim SH; Kim KW; Jhoo JH; Woo JI
    Psychiatry Clin Neurosci; 2001 Aug; 55(4):373-7. PubMed ID: 11442888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic predisposition to Parkinson's disease: CYP2D6 and HFE in the Faroe Islands.
    Halling J; Petersen MS; Grandjean P; Weihe P; Brosen K
    Pharmacogenet Genomics; 2008 Mar; 18(3):209-12. PubMed ID: 18300942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.